HER-2和ER、PR在乳腺癌中的表达及其意义  

Expression of HER-2,ER and PR in the Breast Cancer and It's Significance

作　　者：陈世荣[1] 樊峰[1] 赵一平[1] 

机构地区：[1]苏州市立医院总部病理科,江苏苏州215002

出　　处：《苏州大学学报（医学版）》2007年第5期745-747,共3页Suzhou University Journal of Medical Science

摘　　要：目的探讨HER-2、ER和PR在乳腺癌中的表达及其临床意义。方法采用免疫组化方法检测253例乳腺癌组织中HER-2、ER和PR的表达情况,并进行统计学分析。结果HER-2、ER和PR在乳腺癌组织中的表达率分别为41.1%、39.5%和41.9%。在89例腋窝淋巴结转移的乳腺癌组织中HER-2、ER和PR的表达率分别为79.8%、29.2%和31.5%。HER-2的表达与乳腺癌组织学分化成负相关,而与其转移潜能成正相关;ER、PR的表达与乳腺癌组织学分化成正相关,与其转移潜能成负相关。结论HER-2和ER、PR与乳腺癌的发生、发展密切相关,可作为判断乳腺癌预后的重要指标;可通过对HER-2、ER和PR的检测为临床选择用药提供依据。Objective To study the expression and clinical significance of HER-2,ER and PR in breast cancer. Method Immunohistochemistry method was used to analyze the expression of HER-2, ER and PR in 253 cases of breast cancers. Results Positive expression rates of HER-2, ER and PR in 253 cases of breast cancers were 41.1%, 39.5% and 41.9% respectively. In 89 cases of breast cancers with the lymph node metastasis , the positive rates of expression of HER-2,ER and PR were 79.8%,29.2% and 31.5% respectively. The expression of HER-2 was positive related to lymph node metastasis, but negative related to differentiation of breast cancer. The expression of ER and PR was negative related to lymph node metastasis, but positive related to differentiation of breast cancer. Conclusion Expression of HER-2, ER and PR are involved mainly in breast carcinogenesis and they are associated with prognosis of breast cancer. Measurement of HER-2, ER and PR in the breast cancers can be used to evaluate prognosis and guide clinical treatment .

关 键 词：乳腺癌 HER-2 雌激素受体 孕激素受体 免疫组化 

分 类 号：R737.9[医药卫生—肿瘤]